Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
These therapies mimic incretin hormones, helping regulate blood glucose levels by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetitemaking them highly effective for both glycemic control and weight management
PMID 26255881
In small studies, most patients with chronic knee pain or chronic bladder pain reported major improvement after BPC157 treatment
GIP (glucose-dependent insulinotropic polypeptide) was historically considered primarily a glucose-dependent insulin secretagogue, but tirzepatide's development revealed additional metabolic roles: Central appetite regulation : GIP receptors in the hypothalamus and brainstem contribute to satiety signaling through pathways distinct from GLP-1 Adipose tissue effects : GIP receptors on adipocytes modulate lipid storage and adipokine secretion Beta-cell protection : GIP signaling supports pancreatic beta-cell survival and proliferation Bone metabolism : GIP has anti-resorptive effects on bone, potentially mitigating osteoporosis risk during weight loss GLP-1 receptor agonism provides complementary glucose-lowering and appetite-suppressing effects, as described above
Exosomes derived miR-126 attenuates oxidative stress and apoptosis from ischemia and reperfusion injury by targeting ERRFI1
US$ 21.51
US$ 21.70
US$ 25.40
